Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Emergent Product Development Seattle LLC

Criteria

Inclusion Criteria:

• Must meet American College of Rheumatology criteria for rheumatoid arthritis with functional class I to III.

• Rheumatoid arthritis disease onset at >16 years of age and duration of disease at least 6 months.

• Men or women of nonchildbearing potential (WONCBP), aged 20 to 70 years, inclusive at the screening visit.

Exclusion Criteria:

• Any significant health problems other than rheumatoid arthritis.

• Treatment of greater than 10 mg of prednisone per day.

• Therapy with immunosuppressants within 6 months before study day 1